;PMID: 10804287
;source_file_735.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:43..93] = [t:43..93]
;2)section:[e:97..184] = [t:97..184]
;3)section:[e:188..337] = [t:188..337]
;4)sentence:[e:341..456] = [t:341..456]
;5)sentence:[e:457..591] = [t:457..591]
;6)sentence:[e:592..1060] = [t:592..1060]
;7)sentence:[e:1061..1149] = [t:1061..1149]
;8)sentence:[e:1150..1246] = [t:1150..1246]
;9)sentence:[e:1247..1355] = [t:1247..1355]
;10)section:[e:1359..1404] = [t:1359..1404]

;section 0 Span:0..38
;Jpn J Cancer Res  2000 Apr;91(4):395-8
(SEC
  (FRAG (NNP:[0..3] Jpn) (NNP:[4..5] J) (NNP:[6..12] Cancer) (NNP:[13..16] Res)
        (CD:[18..22] 2000) (.:[23..30] Apr;91-LRB-) (CD:[30..32] 4-RRB-)
        (CD:[32..36] :395) (::[36..37] -) (CD:[37..38] 8)))

;sentence 1 Span:43..93
;Mutation of the SRC gene in endometrial carcinoma.
;[59..62]:gene-rna:"SRC"
;[71..92]:malignancy:"endometrial carcinoma"
(SENT
  (NP-HLN
    (NP (NN:[43..51] Mutation))
    (PP (IN:[52..54] of)
      (NP (DT:[55..58] the) (NN:[59..62] SRC) (NN:[63..67] gene)))
    (PP (IN:[68..70] in)
      (NP (JJ:[71..82] endometrial) (NN:[83..92] carcinoma)))
    (.:[92..93] .)))

;section 2 Span:97..184
;Sugimura M, Kobayashi K, Sagae S, Nishioka Y, Ishioka S, Terasawa K, Tokino
;T,  Kudo R.
(SEC
  (FRAG (NNP:[97..105] Sugimura) (NNP:[106..108] M,) (NNP:[109..118] Kobayashi)
        (NNP:[119..120] K) (,:[120..121] ,) (NNP:[122..127] Sagae)
        (NNP:[128..130] S,) (NNP:[131..139] Nishioka) (NNP:[140..141] Y)
        (,:[141..142] ,) (NNP:[143..150] Ishioka) (NNP:[151..153] S,)
        (NNP:[154..162] Terasawa) (NNP:[163..164] K) (,:[164..165] ,)
        (NNP:[166..172] Tokino) (NNP:[173..174] T) (,:[174..175] ,)
        (NNP:[177..181] Kudo) (NNP:[182..184] R.)))

;section 3 Span:188..337
;Department of Obstetrics and Gynecology, Cancer Research Institute, Sapporo 
;Medical University School of Medicine, Chuo-ku, Sapporo 060-0061, Japan.
(SEC
  (FRAG (NNP:[188..198] Department) (IN:[199..201] of)
        (NNP:[202..212] Obstetrics) (CC:[213..216] and)
        (NNP:[217..227] Gynecology) (,:[227..228] ,) (NNP:[229..235] Cancer)
        (NNP:[236..244] Research) (NNP:[245..254] Institute) (,:[254..255] ,)
        (NNP:[256..263] Sapporo) (NNP:[265..272] Medical)
        (NNP:[273..283] University) (NNP:[284..290] School) (IN:[291..293] of)
        (NNP:[294..302] Medicine) (,:[302..303] ,) (NNP:[304..308] Chuo)
        (::[308..309] -) (NN:[309..311] ku) (,:[311..312] ,)
        (NNP:[313..320] Sapporo) (CD:[321..324] 060) (CD:[324..329] -0061)
        (,:[329..330] ,) (NNP:[331..336] Japan) (.:[336..337] .)))

;sentence 4 Span:341..456
;Recently, an activating mutation of the SRC gene has been implicated in about
; one-tenth of advanced colon cancers.
;[381..384]:gene-rna:"SRC"
;[433..455]:malignancy:"advanced colon cancers"
(SENT
  (S
    (ADVP-TMP (RB:[341..349] Recently))
    (,:[349..350] ,)
    (NP-SBJ-1
      (NP (DT:[351..353] an) (VBG:[354..364] activating)
          (NN:[365..373] mutation))
      (PP (IN:[374..376] of)
        (NP (DT:[377..380] the) (NN:[381..384] SRC) (NN:[385..389] gene))))
    (VP (VBZ:[390..393] has)
      (VP (VBN:[394..398] been)
        (VP (VBN:[399..409] implicated)
          (NP-1 (-NONE-:[409..409] *))
          (PP (IN:[410..412] in)
            (NP
              (NP (RB:[413..418] about) (NN:[420..429] one-tenth))
              (PP (IN:[430..432] of)
                (NP (VBN:[433..441] advanced) (NN:[442..447] colon)
                    (NNS:[448..455] cancers))))))))
    (.:[455..456] .)))

;sentence 5 Span:457..591
;The SRC 531 mutation results in truncation  of SRC directly C-terminal to the
;regulatory Tyr 530 and appears to activate the  Tyr 530.
;[461..464]:gene-rna:"SRC"
;[465..468]:variation-location:"531"
;[469..477]:variation-event:"mutation"
;[489..499]:variation-type:"truncation"
;[504..507]:gene-rna:"SRC"
;[550..553]:variation-location:"530"
;[587..591]:variation-location:"530."
(SENT
  (S
    (NP-SBJ (DT:[457..460] The) (NN:[461..464] SRC) (CD:[465..468] 531)
            (NN:[469..477] mutation))
    (VP
      (VP (VBZ:[478..485] results)
        (PP-CLR (IN:[486..488] in)
          (NP
            (NP (NN:[489..499] truncation))
            (PP (IN:[501..503] of)
              (NP
                (NP (NN:[504..507] SRC))
                (ADJP (RB:[508..516] directly) (NN:[517..518] C)
                      (HYPH:[518..519] -) (JJ:[519..527] terminal)
                  (PP (TO:[528..530] to)
                    (NP (DT:[531..534] the) (JJ:[535..545] regulatory)
                        (NN:[546..549] Tyr) (CD:[550..553] 530)))))))))
      (CC:[554..557] and)
      (VP (VBZ:[558..565] appears)
        (S
          (NP-SBJ (-NONE-:[565..565] *))
          (VP (TO:[566..568] to)
            (VP (VB:[569..577] activate)
              (NP (DT:[578..581] the) (NN:[583..586] Tyr) (CD:[587..590] 530)))))))
    (.:[590..591] .)))

;sentence 6 Span:592..1060
;To investigate whether mutation of SRC plays an important role in the 
;development and progression of gynecological tumors, we performed mutational 
;analysis of the entire coding region of SRC in 70 ovarian carcinomas, 68 
;endometrial carcinomas and 3 endometrial stromal sarcomas by means of
;polymerase  chain reaction-single strand conformation polymorphism (PCR-SSCP)
;followed by  nucleotide sequencing and restriction fragment length
;polymorphism (RFLP)  analysis.
;[627..630]:gene-rna:"SRC"
;[694..714]:malignancy:"gynecological tumors"
;[781..784]:gene-rna:"SRC"
;[791..809]:malignancy:"ovarian carcinomas"
;[815..837]:malignancy:"endometrial carcinomas"
;[844..872]:malignancy:"endometrial stromal sarcomas"
;[885..895]:gene-protein:"polymerase"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[592..592] *))
      (VP (TO:[592..594] To)
        (VP (VB:[595..606] investigate)
          (SBAR (IN:[607..614] whether)
            (S
              (NP-SBJ
                (NP (NN:[615..623] mutation))
                (PP (IN:[624..626] of)
                  (NP (NN:[627..630] SRC))))
              (VP (VBZ:[631..636] plays)
                (NP (DT:[637..639] an) (JJ:[640..649] important)
                    (NN:[650..654] role))
                (PP (IN:[655..657] in)
                  (NP
                    (NP (DT:[658..661] the) (NN:[663..674] development)
                        (CC:[675..678] and) (NN:[679..690] progression))
                    (PP (IN:[691..693] of)
                      (NP (JJ:[694..707] gynecological) (NNS:[708..714] tumors)))))))))))
    (,:[714..715] ,)
    (NP-SBJ (PRP:[716..718] we))
    (VP (VBD:[719..728] performed)
      (NP
        (NP (JJ:[729..739] mutational) (NN:[741..749] analysis))
        (PP (IN:[750..752] of)
          (NP
            (NP (DT:[753..756] the) (JJ:[757..763] entire)
                (NN:[764..770] coding) (NN:[771..777] region))
            (PP (IN:[778..780] of)
              (NP (NN:[781..784] SRC)))))
        (PP-LOC (IN:[785..787] in)
          (NP
            (NP (CD:[788..790] 70)
               (JJ:[791..798] ovarian) (NNS:[799..809] carcinomas))
            (,:[809..810] ,)
            (NP (CD:[811..813] 68)
               (JJ:[815..826] endometrial) (NNS:[827..837] carcinomas))
            (CC:[838..841] and)
            (NP (CD:[842..843] 3)
               (JJ:[844..855] endometrial) (JJ:[856..863] stromal)
               (NNS:[864..872] sarcomas)))))
      (PP-MNR (IN:[873..875] by)
        (NP
          (NP (NNS:[876..881] means))
          (PP (IN:[882..884] of)
            (NP
              (NP
                (NP
                  (NML (NN:[885..895] polymerase) (NN:[897..902] chain)
                       (NN:[903..911] reaction))
                  (HYPH:[911..912] -)
                  (NML
                    (NML (JJ:[912..918] single) (NN:[919..925] strand))
                    (NN:[926..938] conformation) (NN:[939..951] polymorphism)))
                (NP (-LRB-:[952..953] -LRB-) (NN:[953..956] PCR)
                    (HYPH:[956..957] -) (NN:[957..961] SSCP)
                    (-RRB-:[961..962] -RRB-)))
              (VP (VBN:[963..971] followed)
                (NP (-NONE-:[971..971] *))
                (PP (IN:[972..974] by)
                  (NP-LGS
                    (NP (NN:[976..986] nucleotide) (NN:[987..997] sequencing))
                    (CC:[998..1001] and)
                    (NP
                      (NML
                        (NML (NN:[1002..1013] restriction)
                             (NN:[1014..1022] fragment) (NN:[1023..1029] length)
                             (NN:[1030..1042] polymorphism))
                        (NML (-LRB-:[1043..1044] -LRB-) (NN:[1044..1048] RFLP)
                             (-RRB-:[1048..1049] -RRB-)))
                      (NN:[1051..1059] analysis))))))))))
    (.:[1059..1060] .)))

;sentence 7 Span:1061..1149
;We found one truncated mutation at codon 531 (Gln to Stop) in an  endometrial
;carcinoma.
;[1074..1092]:variation-type:"truncated mutation"
;[1096..1105]:variation-location:"codon 531"
;[1107..1110]:variation-state-original:"Gln"
;[1114..1118]:variation-state-altered:"Stop"
;[1127..1148]:malignancy:"endometrial carcinoma"
(SENT
  (S
    (NP-SBJ (PRP:[1061..1063] We))
    (VP (VBD:[1064..1069] found)
      (NP (CD:[1070..1073] one)
         (VBN:[1074..1083] truncated) (NN:[1084..1092] mutation))
      (PP-LOC (IN:[1093..1095] at)
        (NP
           (NN:[1096..1101] codon) (CD:[1102..1105] 531)
          (PRN (-LRB-:[1106..1107] -LRB-)
            (NP
              (NP (NN:[1107..1110] Gln))
              (PP (TO:[1111..1113] to)
                (NP (NN:[1114..1118] Stop))))
            (-RRB-:[1118..1119] -RRB-))))
      (PP-LOC (IN:[1120..1122] in)
        (NP (DT:[1123..1125] an)
           (JJ:[1127..1138] endometrial) (NN:[1139..1148] carcinoma))))
    (.:[1148..1149] .)))

;sentence 8 Span:1150..1246
;However, we found no mutation of this gene in ovarian  carcinoma or
;endometrial stromal sarcoma.
;[1188..1192]:gene-rna:"gene"
;[1196..1214]:malignancy:"ovarian  carcinoma"
;[1218..1245]:malignancy:"endometrial stromal sarcoma"
(SENT
  (S
    (ADVP (RB:[1150..1157] However))
    (,:[1157..1158] ,)
    (NP-SBJ (PRP:[1159..1161] we))
    (VP (VBD:[1162..1167] found)
      (NP
        (NP (DT:[1168..1170] no) (NN:[1171..1179] mutation))
        (PP (IN:[1180..1182] of)
          (NP (DT:[1183..1187] this) (NN:[1188..1192] gene))))
      (PP (IN:[1193..1195] in)
        (NP
          (NP (JJ:[1196..1203] ovarian) (NN:[1205..1214] carcinoma))
          (CC:[1215..1217] or)
          (NP (JJ:[1218..1229] endometrial) (JJ:[1230..1237] stromal)
              (NN:[1238..1245] sarcoma)))))
    (.:[1245..1246] .)))

;sentence 9 Span:1247..1355
;Our results suggest that mutation of  SRC may be implicated in a small
;proportion of endometrial carcinomas.
;[1285..1288]:gene-rna:"SRC"
;[1332..1354]:malignancy:"endometrial carcinomas"
(SENT
  (S
    (NP-SBJ (PRP$:[1247..1250] Our) (NNS:[1251..1258] results))
    (VP (VBP:[1259..1266] suggest)
      (SBAR (IN:[1267..1271] that)
        (S
          (NP-SBJ-1
            (NP (NN:[1272..1280] mutation))
            (PP (IN:[1281..1283] of)
              (NP (NN:[1285..1288] SRC))))
          (VP (MD:[1289..1292] may)
            (VP (VB:[1293..1295] be)
              (VP (VBN:[1296..1306] implicated)
                (NP-1 (-NONE-:[1306..1306] *))
                (PP-CLR (IN:[1307..1309] in)
                  (NP
                    (NP (DT:[1310..1311] a) (JJ:[1312..1317] small)
                        (NN:[1318..1328] proportion))
                    (PP (IN:[1329..1331] of)
                      (NP (JJ:[1332..1343] endometrial)
                          (NNS:[1344..1354] carcinomas)))))))))))
    (.:[1354..1355] .)))

;section 10 Span:1359..1404
;PMID: 10804287 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1359..1363] PMID) (::[1363..1364] :) (CD:[1365..1373] 10804287)
        (NN:[1374..1375] -LSB-) (NNP:[1375..1381] PubMed) (::[1382..1383] -)
        (NN:[1384..1391] indexed) (IN:[1392..1395] for)
        (NNP:[1396..1404] MEDLINE-RSB-)))
